

20 March 2020

# ASX ANNOUNCEMENT

## CORONAVIRUS MITIGATION STRATEGY

Admedus Limited (ASX: AHZ) (**Admedus** or the **Company**) expects the coronavirus impact on the Company's operations to be minimal. A coronavirus mitigation strategy has been implemented to limit the risk of an interruption to the continuity of supply and operations.

The Company continues manufacturing product for LeMaitre Vascular Inc. LeMaitre's feedback on its CardioCel<sup>®</sup> and VascuCel<sup>®</sup> patch sales remains positive with no downturn in customer orders at this stage.

Notably, the first-in-human 15 patient trial of the Company's ADAPT<sup>®</sup> single-piece 3D aortic valve for surgical aortic valve replacement at the Universities' Hospital, Leuven (in Belgium) remains on track to proceed as scheduled with the first patient expected to undergo surgery by month's end. However, disruption due to COVID-19 demands on hospital resources may delay this into April 2020.

The chief disruption to date is to corporate and medical conferences due to event cancellations and travel restrictions. Importantly, our Advisory Board of Physicians continues to meet, holding its next meeting via video conference next week.

Key additional measures implemented as part of the Company's coronavirus mitigation strategy effect:

- travel policy,
- personnel practices, and
- manufacturing continuity.

Excluding manufacturing and R&D, staff and contractors will work from home during the pandemic. While monitoring the situation closely, we want to reassure all shareholders the Company continues operating to plan and key projects progress as schedule.

**Admedus Limited**


**Registered Office:**

Toowong Tower, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

**Customer Service:**

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: [info@admedus.com](mailto:info@admedus.com) W: [admedus.com](http://admedus.com)



Yours faithfully,

A handwritten signature in black ink, appearing to be 'Wayne Paterson'.

Wayne Paterson  
Managing Director and CEO

**About Admedus Limited (ASX: AHZ)**

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

**Authorisation and Additional information**

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

**For more information:**

Ms Kyahn Williamson

WE Communications

E: [WE-AUAdmedus@we-worldwide.com](mailto:WE-AUAdmedus@we-worldwide.com)

P: +61 401 018 828

[www.admedus.com](http://www.admedus.com)

Twitter: @Admedus

Facebook: [www.facebook.com/admedus/](http://www.facebook.com/admedus/)